Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | BMC Musculoskeletal Disorders

Fig. 5

From: Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy

Fig. 5

Biomechanical testing of femurs and tibias. A significant increase in both maximum force and stiffness was measured in the Act-R-Fc treated mice compared to the control group. However there was no statistical significance between the ActRIIB-Fc-treated and control running groups. N = 7-9 per group. # = p < 0.05 compared to PBS, * = p < 0.05 compared to PBS-R

Back to article page